Brookline Capital Downgrades Oncternal Therapeutics to Hold
Portfolio Pulse from Benzinga Newsdesk
Brookline Capital has downgraded Oncternal Therapeutics from Buy to Hold, indicating a change in the analyst's outlook on the company's stock.
September 12, 2024 | 3:16 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Brookline Capital has downgraded Oncternal Therapeutics from Buy to Hold, suggesting a less optimistic view on the stock's potential performance.
The downgrade from Buy to Hold by Brookline Capital indicates a shift in the analyst's perspective, potentially leading to a negative short-term impact on the stock price as investors may reassess their positions based on this new rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100